Twist Nets $149M and Several Collaborations – Clinical OMICs News

Twist Bioscience Corporation has snagged several partnerships as it secures more than $140 million from a public offering. These include deals with SOPHiA GENETICS around data analysis, as well as development of target enrichment tools and library preparation kit deals with GenapSys and Miroculus.

The SOPHiA deal offers Twists customers access to SOPHiAs Platform for advanced genomic analysis. Together, the partners say, the technologies will allow a customer to go from sample to interpretation quickly and efficiently. Twist provides high fidelity double stranded DNA probes for enrichment of target regions with no unexpected dropouts and unparalleled specificity even at high sequencing depths, according to their website.

Sequencing the whole genome is typically expensive and often does not provide the depth of information needed for individual genes and the role they play in complex diseases. Target enrichment enables genomic sequencing efforts to be focused in specific regions of interest, which reduces cost and analysis time. Genomic solutions that combine Twist NGS enrichment solutions along with the SOPHiA AI-powered Platform for advanced DNA analysis are designed to support the implementation of NGS application for somatic and germline testing.

SOPHiAs mission is to democratize access to Data-Driven Medicine all around the world.With the addition of SOPHiAs technology to Twists advanced products, clinical researchers will benefit from end-to-end, highly-accurate and reliable genomic solutions, commented Jurgi Camblong CEO and Co-founder of SOPHiA GENETICS. The combined solution will ultimately help experts precisely detect and characterize genomic mutations and use that information to improve outcomes.

Genomics research is enabling a shift from broad-based one-size-fits-all approach to a personalized experience, commented Emily M. Leproust, Ph.D., CEO, and co-founder of Twist. Pairing our industry-leading, rapidly customizable enrichment efficiency with SOPHiAs robust analytical platform provides customers an important solution to achieve clinically actionable data while saving on sequencing costs. We are excited to work with SOPHiA to provide this new combined offering to clinical researchers around the world.

Twist Bioscience is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by writing DNA on a silicon chip. Twist is using this technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development.

View post:
Twist Nets $149M and Several Collaborations - Clinical OMICs News